Clopidogrel Pharmacogenetic Score System (CPASS)

Clopidogrel Pharmacogenetic Score System Established for Chinese Patients

The aim of the present study is to evaluate candidate variables,including Cytochrome P450 2C19(CYP2C19) genotypes, clinical and demographic variables,to establish a simple risk score that can be easily adopted by clinicians to identify patients who are at risk for HPR and composite cardiovascular outcomes in Chinese Han patients treated with dual antiplatelet therapy.

Study Overview

• Status: Unknown
• Conditions: Acute Coronary Syndrome

Detailed Description

There is a large inter-individual variability of biological antiplatelet responsiveness in patients treated with clopidogrel. Our previous study suggested that in clopidogrel treated Chinese patients with acute coronary syndromes(ACS),carriers of at least one CYP2C19 loss-of-function allele could predict greater risk of high on-treatment platelet reactivity (HPR), with the impact mainly attributing to CYP2C19*2. But as we know, CYP2C19*2 could only explain a small proportion of the variability. Various clinical and demographic variables have been considered to influence response to antiplatelet therapy.

Study objectives:

The present study aims to evaluate candidate variables,including CYP2C19 gene polymorphisms, clinical and demographic variables,to establish a simple risk score to identify patients who are at risk for HPR and composite cardiovascular outcomes .

Study design:

Step 1: Population enrollment and medication This mono-center study will be conducted in General Hospital of Chinese People's Liberation Army. Consecutive patients more than 18 years old admitted for ACS will be recruited after giving informed consents. After admission, all enrolled patients will be treated with 100 mg aspirin and 75mg clopidogrel per day. A loading dose of 300 mg clopidogrel will be given to patients undergoing coronary angiography.

Step 2: Clinical and demographic data collection A detailed demographic and medical data will be extracted from medical charts and prescription records. For the development of the risk score system, we will chose variables that are available in routine clinical practice. Clinical candidate variables include smoking history, diabetes,hypertension, renal failure with a serum creatinine>1.5mg/dL-1, hypercholesterolemia, left ventricular dysfunction, age, gender, acute coronary syndrome on admission and co-medication with statins, calcium channel inhibitor, and proton pump inhibitors.

Step 3 : Platelet function measurements and Genotyping After 5 days maintenance dose of clopidogrel administration, blood samples will be drawn for light transmittance aggregometry (LTA) testing, using an APACT-4 aggregometer (LABiTec, Germany). The magnitude of on-treatment platelet reactivity was quantified using LTA with 20µmol/L ADP(adenosine disphosphate) as the agonist. Aggregation was expressed as the maximal percentage change in light transmittance from baseline, with platelet-poor plasma as the reference.

Genomic DNA will be extracted from the peripheral blood leucocytes of each patient. The loss of function alleles, CYP2C19*2 (rs4244285) and CYP2C19*3 (rs4986893), will be genotyped by the polymerase chain reaction(PCR)-ligase detection reactions(LDR)sequencing method.

Step 4: Follow-up At one year, the incidence of composite cardiovascular outcomes will be assessed by review of the patients'charts on re-admission or by telephone interview. Telephone interviewers are blinded with respect to the results of platelet aggregation and genotypes.

Step 5: Statistical analysis and development of risk score Logistic regression and Cox proportional hazards survival regression will be used to develop the risk score system with the candidate variables including clinical and demographic variables, CYP2C19 genotypes, and platelet aggregation.

• Study Type: Observational
• Enrollment (Anticipated): 500

Contacts and Locations

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100853
      • Institute of Geriatric Cardiology, General Hospital of Chinese People's Liberation Army
    • Beijing, Beijing, China, 100853
      • Institute of Geriatric Cardiology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

consecutive patients treated with maintenance dose of clopidogrel

Description

Inclusion criteria:

• Patients more than 18 years old
• Admitted for ACS to the Department of Geriatric Cardiology, General Hospital of Chinese People's Liberation Army
• The diagnosis of ACS according to the American Heart Association/American College of Cardiology (AHA/ACC) criteria, 2012

Exclusion criteria:

• Known contraindication to dual anti-platelet therapy
• History of chronic inflammatory disease
• Steroidal and non-steroidal anti-inflammatory drugs use
• Previous administration of antiplatelet drugs within 1 month before coronary artery angiography
• Illicit drug abuse
• Significant bleeding tendency
• Cerebrovascular events within 3months
• Major surgery within 4 weeks

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Clopidogrel treated patients; A consecutive cohort with 500 cases treated with 75mg/day maintenance dose of clopidogrel.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
high on-treatment platelet reactivity (HPR)	A threshold of 50% maximal post-procedural aggregation was chosen to define HPR.	After 30 days maintenance dose of clopidogrel administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Composite ischemia cardiovascular outcomes	The composite of death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke , urgent coronal revascularization,and stent thrombosis.	1 year
Hemorrhagic complications	The primary clinical safety end point of the study is the 1-year incidence of combined major and minor bleeding events defined according to the Thrombolysis in Myocardial Infarction (TIMI) criteria . TIMI major bleedings include hemoglobin reduction >5 g/dL(with or without obvious bleeding spots) , intracranial hemorrhages, and cardiac tamponade.TIMI minor bleedings include hemoglobin reduction >3 g/dL but ≤5 g/dL ,macroscopic hematuria,hemoptysis,hematemesis,ecchymoma,mucous membrane and other minor bleedings.	1 year

Collaborators and Investigators

• Sponsor: Chinese PLA General Hospital
• Investigators: Principal Investigator: Tong Yin, Dr., Institute of Geriatric Cardiology, General Hospital of People's Liberation Army, Beijing China

Publications and helpful links

General Publications

• Zhang L, Chen Y, Jin Y, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Li X, Li Y, Zhang Y, Lu C, Yin T. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. Thromb Res. 2013 Jul;132(1):81-7. doi: 10.1016/j.thromres.2013.05.006. Epub 2013 May 29.

Study record dates

Study Major Dates

• Study Start: January 1, 2014
• Primary Completion (Anticipated): January 1, 2015
• Study Completion (Anticipated): January 1, 2015

Study Registration Dates

• First Submitted: November 18, 2013
• First Submitted That Met QC Criteria: November 18, 2013
• First Posted (Estimate): November 25, 2013

Study Record Updates

• Last Update Posted (Estimate): November 25, 2013
• Last Update Submitted That Met QC Criteria: November 18, 2013
• Last Verified: November 1, 2013

More Information

Terms related to this study

• Keywords: platelet aggregation; clopidogrel; pharmacogenomics; CYP2C19; score system; ischemic cardiovascular outcomes; hemorrhage complications
• Additional Relevant MeSH Terms: Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Acute Coronary Syndrome
• Other Study ID Numbers: 2012042